Patent · US Active

Dry powder inhaler

US9066957B2 · kind B2 · utility

1Cited by
1References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 6, 2014
Grant dateJun 30, 2015
Priority date—
Expiry dateOct 6, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61M2206/16
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 μg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 μg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.